甘精胰岛素联合阿卡波糖治疗2型糖尿病的疗效观察

目的：探讨甘精胰岛素联合阿卡波糖治疗2型糖尿病的临床效果。方法方便选取2012年10月—2013年12月期间在该院收治的2型糖尿病患者100例,随机分为研究组和对照组(每组50例)。研究组采用甘精胰岛素联合阿卡波糖治疗,对照组给予预混胰岛素(诺和灵30R)治疗。治疗周期均为12周,治疗后观察两组治患者空腹血糖(FBG)、餐后2 h血糖(2 h PBG)糖化血红蛋白(HbAlc)的变化、低血糖发生率及胃肠道不良反应。结果两组治疗后患者FBG、2 h PBG HbAlc均明显降低,其中治疗后两组FBG,HbAlc水平比较差异无统计学意义(P>0.05),两组患者2 h PBG水平比较差异具有统计学意义(P<0.05)；研究组和对照组低血糖发生率分别为3例(6.0%)和10例(20.0%),两组比较差异具有统计学意义(P<0.05)。结论甘精胰岛素联合阿卡波糖能较好的控制2型糖尿病患者的血糖,且患者低血糖发生率低,值得临床推广使用。

Efficacy of Insulin Glargine Combined with Acarbose Treatment of Type 2 Diabetes

Objective To investigate the insulin glargine combined with the clinical effect of acarbose in type 2 diabetes. Methods Convenient selection from October 2012 to December 2013 in our hospital treated 100 patients with type 2 dia-betes were randomly divided into study group and control group (n = 50). Study group received insulin glargine combined with acarbose treatment, control group received premixed insulin (Novolin 30R) treatment. Treatment period is 12 weeks af-ter treatment were observed treatment of patients fasting blood glucose(FBG), postprandial 2 h glucose adverse reactions (2 h PBG) glycated hemoglobin (HbAlc) changes in the incidence of hypoglycemia and gastrointestinal tract. Results After treat-ment, patients FBG, 2 h PBG HbAlc were significantly decreased in both groups after which treatment FBG, HbAlc level difference was not statistically significant(P> 0.05), two groups of patients 2 h PBG level and the difference was statistically significant(P<0.05 ); the study group and the control group, the incidence of hypoglycemia were 3 cases (6.0%) and 10 pa-tients (20.0%), the difference was statistically significant (P<0.05). Conclusion Insulin Glargine combined acarbose can better glucose control in type 2 diabetes, and the incidence of hypoglycemia in patients with low, worthy of clinical use.